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Abstract
Background: The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability
and working life.
Methods: The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice
questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients
(ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients.
Results: Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working
age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS)
(39 %) and psoriatic arthritis (PsA) (36 %). Respondents were working full-time (45 %), part-time (8 %) or had retired (22 %);
15 % were unemployed (for reasons linked to the disease or for other reasons, students or housewives). Patients reported
disability (39 %), were receiving disability benefits (34 %), were experiencing important limitations that were hindering
their professional development/career (36 %) and some had to change/leave their job or lost it because of SpA (21 %).
Employed respondents (n = 383) had worked on average 32.2 h in the last 7 days. More hours of work were lost over the
last 7 days due to SpA (2.39 h vs 1.67 h). The indirect costs of the disease amounted to €106/week for patients reporting
well-being/good physical conditions/improvement and €216/week for those reporting permanent impairment.
Conclusions: Most patients were in the midst of their productive years and were experiencing considerable difficulties in
carrying out their job because of the disease: half of them reported disability and one third were experiencing important
limitations in their career perspective.
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Background
Major advances have occurred in the diagnosis and classi-
fication of spondyloarthritis (SpA) over the last 10 years,
especially since spinal inflammation was demonstrated on
magnetic resonance imaging (MRI) in the absence of
radiographic evidence of change [1]. The changes were
formalized in the revised versions of the Assessment of
SpondyloArthritis International Society (ASAS) classifica-
tion criteria for axial (ax) [2] and peripheral SpA [3].
Thanks to these criteria, patients with axial SpA without
radiographic evidence of sacroiliitis can now be classified
as having non-radiographic axSpA, a form which does not
appear to differ significantly from radiographic axSpA in
terms of the main clinical manifestations, disease activity,
pain, quality of life and response to anti-tumor necrosis
factor (anti-TNF) therapy [4–6]. Differences between pa-
tients with non-radiographic and radiographic axSpA have
been found in age, symptom duration, human leukocyte
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antigen (HLA)-B27 positivity [7] and gender distribution.
Although less inflammation (i.e., lower C-reactive protein
and less evidence of spinal inflammation on MRI) and less
impairment in spinal mobility have been observed in non-
radiographic axSpA than in the axSpA, the two conditions
are associated with a similar burden in terms of disease
activity, physical function and health ratio quality of life
(HR-QoL) impairment [8]. ASAS classification criteria are
also important because they enable detection of early SpA,
so that treatment can be introduced earlier than in the
past when the average delay in diagnosis was about
10 years [9]. Of course, former classification criteria for
specific subtypes of SpA, such as the modified New York
Criteria for ankylosing spondylitis (AS) [10] or Classifica-
tion Criteria for Psoriatic Arthritis (CASPAR) for psoriatic
arthritis (PsA) [11] remain valid to classify particular
forms of the disease.
Before the introduction of the ASAS criteria, the glo-
bal prevalence of SpA was calculated to be approxi-
mately 1 %, with notable variability, ranging from 0.01 %
in Japan to 2.5 % in Northern Arctic populations. The
recognition of non-radiographic axSpA will have a con-
siderable impact on the prevalence of SpA, because
many patients who had an unclassifiable axSpA can now
be classified according to the ASAS criteria [1, 8].
The increase in the prevalence of SpA has notable
socioeconomic implications. By definition, SpA is a
disease that occurs in young adults at the peak of their
productive lifespan [2]. Moreover, it is associated with a
considerable burden in terms of restrictions in activities
of daily living [12, 13], reduction in health-related quality
of life (HR-QoL) [13, 14] and in work productivity, and
in terms of unemployment [15–17].
The reduction in work productivity is an important
component of the indirect costs of SpA, which are typ-
ically calculated in terms of absenteeism and presentee-
ism using tools such as the Work Productivity and
Activity Impairment Questionnaire in AS (WPAI) [18].
Absenteeism is defined as the quantity of sick leave
either specifically due to the disease itself or, in the
event that it is difficult to distinguish between sick
leave due to the disease itself and sick leave due to con-
comitant or incident diseases, the total amount of sick
leave expressed as days in a year or hours per week.
Presenteeism is defined as patient-reported reduced
productivity at work [18]. Caution is required in the
extrapolation of data from one country to another, be-
cause findings on work productivity and unemployment
are affected by a number of local factors, primarily the
local unemployment/disability benefit system [19].
We carried out a survey in Italy called Atlantis (an
underwater world that we would like to bring to light),
which was designed to establish how the diagnostic work-
up and management of SpA in Italy is experienced by the
patients, and assess the impact of SpA on daily living,
personal relationships, work disability and working life.
This paper reports findings on work disability and work-
ing life.
Methods
Study characteristics
This was a cross-sectional survey sponsored by the Italian
National Association of Rheumatic Patients (ANMAR). It
was carried out in 17 out of the 20 regions in Italy from 1
January to 31 March 2013 by Doxa-Pharma, a company
experienced in carrying out surveys in the healthcare field,
Table 1 Main features of survey respondents
Sociodemographic characteristics Respondents, %
Gender
Male 56 %
Female 44 %
Age, years
≤30 8 %
31–40 17 %
41–50 26 %
51–60 27 %
61–70 17 %
>70 4 %
Not specified 1 %
Education
Degree/Master’s degree 17 %
High school 45 %
Junior high school 28 %
Primary school 8 %
Not specified 2 %
Marital status
Married/living with partner 64 %
Single 20 %
Divorced/separated/widow(er) 12 %
Not specified 4 %
Residence
North-West 24 %
North-East 26 %
Central regions 26 %
South and Islands 24 %
Diagnosis
Ankylosing spondylitis 41 %
Psoriatic arthritis 39 %
Spondyloartritis with inflammatory bowel disease 10 %
Undifferentiated spondyloarthritis 6 %
Reactive arthritis 4 %
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under the guidance of an experienced rheumatologist
(RR, author), who was the scientific coordinator of the
project. According to Italian regulations, the study did
not require written informed consent because the ques-
tionnaire was completed anonymously. Additional sen-
sitive data were not collected.
Patients and methods
The survey was conducted on patients with a defined
diagnosis of SpA made by a rheumatologist and the
questionnaire was drafted with five sections: (1) personal
details and diagnosis of the patient, including informa-
tion on work status and any welfare benefits granted; (2)
the diagnostic work-up; (3) follow up; (4) impact of the
disease on quality of life; and (5) impact on working life,
including absenteeism and presenteeism. We considered
the indirect costs of the disease in terms of sick leave,
which was defined as the weekly cost due to the hours
of absence from the job because of the disease, and in
terms of presenteeism, which was defined as the quanti-
fication of the weekly cost due to the lower job perform-
ance of the patients because of the disease. The sum of
these two indices, termed the time loss, was defined as
the weekly income that was not produced (indirect cost),
considering the Italian weekly per capita income in
euros in 2012 divided by the standard 44 weeks of work.
The multiple-choice questions focused on work status
and working life (see Additional file 1 for all questions
in detail). Data were collected through two parallel chan-
nels: (1) the survey questionnaire was published on the
web, with a link placed at the official ANMAR website
(www.anmar-italia.it), to be completed by patients who
were willing to do so, and (2) hard copies of the survey
questionnaire were distributed throughout the Italian
regions of interest by ANMAR volunteers, with the sup-
port of specialists at the hospitals with clinics dedicated
to the management of rheumatic patients.
Data analysis
The data were analyzed descriptively. For the open ques-
tions we read all the answers and encoded various items.
Data were expressed in terms of frequency and averages.
Electronic software (SAS and DIANA) was used to per-
form an interpretative reading of these data. Collected
data were analyzed in relation to sociodemographic vari-
ables (sex, age, area of residence) and the type of specific
SpA disease.
Results
A total of 770 subjects took part in the survey. Their
main features are summarized in Table 1.
More respondents were men (56 %). Most of them
were married or living with a partner (64 %), were of
working age (78 % aged ≤60 years; mean age = 50 years)
and educated (62 % had completed high school or had a
university degree). Their distribution throughout Italy
was homogeneous, ranging from 24–26 % in the four
main Italian geographical areas. The subjects were
suffering from AS (41 %), PsA (39 %) SpA with inflamma-
tory bowel diseases (IBD) (10 %), undifferentiated SpA
(6 %) and reactive arthritis (4 %) (Fig. 1). Many patients re-
ported that they had contacted other specialists after the
diagnosis: ophthalmologists 50 %, cardiologists 45 %, der-
matologists 43 %, gastroenterologists 37 %, psychologists
Fig. 1 Main work status in patients with spondyloarthritis
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10 %, specialists in infectious diseases 8 %, pulmonologists
2 %, neurologists 2 %, gynecologists 1 %, endocrinologists
1 %, and neurosurgeons 1 % [20].
Slightly below half of the respondents were working
either full-time (45 %) or part-time (8 %). Nearly one
fourth had retired (22 %) and 15 % were unemployed
(for reasons linked to SpA in 4 % of the cases; the
remaining were students, housewives or individuals who
were unemployed due to reasons other than SpA)
(Fig. 1). Half of the respondents (49 %) reported that
they were disabled (Table 2) and had to cancel or post-
pone commitments because of their disease (50 %) and
13 % declared that they had to do this at least half of the
time. This depended on symptom control.
One third of patients (36 %) experienced important
limitations that hindered their professional development/
career. Of these, 19 % had controlled symptoms, 32 %
were improving and 50 % had uncontrolled symptoms.
One in five patients actually had to change or leave their
job or had actually lost it because of SpA (21 %). Discrim-
ination may have played a role in some cases, because
14 % of subjects reported this, and another 14 % believed
that SpA had had an impact on their salary (Table 2). The
impact on salary also depended on symptom control: 12 %
of the patients with controlled symptoms believed that
their disease had had a negative effect on their salary
compared to 20 % with uncontrolled symptoms. The 383
respondents (49.7 % of the total sample) who were
employed had worked on average 32.2 h in the last 7 days.
Approximately 60 % had actually worked full-time (31 h or
more) (Fig. 2).
Questions about absenteeism revealed that more
hours had been lost over the previous 7 days due to
SpA (on average 2.39 h vs 1.67 h), than for other rea-
sons such as vacation or family commitments. The
hours of absence because of SpA amounted to 59 % of
the hours of absence from the work place and to 7 % of
weekly working hours. The time loss cost was €216 per
week for the patients reporting permanent impairment
and €106 euros for the patients who reported well-
being or an improvement in their physical condition.
Discussion
This survey spearheaded by ANMAR has shown that
patients with SpA experience major disadvantages in
their working life: one half of the respondents claimed
that they were disabled, and one half reported that SpA
interfered significantly with their work commitments;
SpA was the main source of absenteeism and presentee-
ism. What is more, the survey identified a number of
issues that, to our knowledge, have not been investigated
to date: one half experienced restrictions in their work
prospects and career, 21 % had had to change/leave a
job or had lost a job because of SpA, and 14 % had
experienced discrimination at the workplace.
The sample was representative of the SpA population
in terms of gender, age and diagnosis, [1, 21, 22]. Par-
ticipation from all four main geographical areas of Italy
was almost the same for each (24–26 %). The collec-
tion of data both via the website and distribution at
hospital outpatient clinics ensured that there was no
Table 2 Impact on working life
Reported consequences of SpA Respondents, %
Disability 49 %
Receives disability benefits 34 %
Has applied for disability benefits 8 %
Cannot work full-time, but does not meet criteria
for disability benefit
7 %
Has to cancel or postpone work commitments
because of SpA
50 %
Does not apply 27 %
Never 23 %
Sometimes 37 %
About half the time 7 %
Most of the time 4 %
All the time 2 %
Limitations to work projects or career in general
because of SpA
48 %
Does not apply 20 %
None 12 %
Negligible 20 %
Minor limitations 12 %
Tangible limitations 15 %
Major limitations 21 %
Had to change/leave a job or lost a job because
of SpA
21 %
Yes 21 %
Does not apply 24 %
No 55 %
Has felt discriminated at work because of SpA 14 %
Yes 14 %
Does not apply 31 %
No 55 %
Fewer raises in salary because of SpA 14 %
Does not apply 44 %
Not at all 36 %
Negligible 6 %
A little 4 %
Quite a bit 7 %
A lot 3 %
SpA spondyloarthritis
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pre-selection of computer-literate patients [23]. Even
so, the survey did include patients who were more
educated than average, as only 28 % of respondents
had not continued after junior high school, whereas
the national average in 2013 was 44 % [23]; this is
probably due to the fact that the elderly (a less edu-
cated generation) were under-represented in the sam-
ple (patients over 60 years of age represented 21 % vs
the 27.2 % in the general population [24].
The employment rate was slightly lower than in the
general population, being 53 % instead of the expected
rate of 58 %, according to the official employment statis-
tics in the general population in Italy in 2013 [25], after
correction for the higher percentage of male individuals
in the survey than in the general population. Discrimin-
ation may have played a role in some cases; in fact,
14 % of the patients reported having the impression of
being treated differently from other colleagues due to
their rheumatic disease. The proportion of SpA patients
receiving disability benefits was nearly five times higher
than the proportion in the general population (34 % vs
7.3 %) [24, 26].
One of our study limitations was the use of a non-
validated questionnaire. However, our findings on work
disability and reduction in productivity, both in terms
of absenteeism and presenteeism, are consistent with
similar published studies, which all report that SpA is
associated with disability and reduction in productivity.
Nevertheless, comparisons between different studies is
difficult because of the differences in patient popula-
tions (e.g., the proportions with manual vs non-manual
occupations, proportions with non-SpA-related comor-
bidities), and in the definition of endpoints (e.g., sick
leave may be total or restricted to leave due to SpA),
and, above all, differences in local employment and
benefit systems [25]. The mean total sick leave was
4 hours per week, which amounts to 26 days of sick
leave a year, which is well within the range reported in
the literature mentioned above.
In our results we also included an assessment of indir-
ect costs, in terms of time loss, which is the sum of sick
leave and presenteeism costs. In this study time loss cost
was €216 per week for the patients with permanent im-
pairment and €106 euros for the patients who were well
or claimed that their physical conditions had improved.
Another limitation of this survey is the lack of infor-
mation on disease duration. However, it has been shown
that productivity is substantially reduced, even in pa-
tients with early SpA (mean disease duration 4.8 years)
[27]. This evidence is cause for major concern, because
the onset of the disease is in young adulthood and it
therefore results in limitations during patients’ most
productive years. Indeed, this prospect was emphasized
by the fact that nearly half of the respondents had the
perception of a loss in their work prospects.
To our knowledge, this is the first survey that docu-
ments the perception of limitations in work prospects and
career, and discrimination at the workplace. A number of
factors have been found to be associated with work
disability and loss of productivity at work. Unemployment
is associated with older age, social deprivation, longer
disease duration, functional impairment, and depression,
whereas absenteeism is associated only with disease activ-
ity and depression, and presenteeism with older age, dis-
ease activity, anxiety, and depression [28]. In particular, in
a cross-sectional self-reported postal survey examining
1447 Swedish respondents with SpA, presenteeism was
associated with a series of disease activity and quality of
life measures, including the Bath Ankylosing Spondylitis
Activity Index (BASDAI), the Bath Ankylosing Spondylitis
Fig. 2 Results (employed/unemployed workers) by the survey
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Functional Index (BASFI), the EuroQoL (EQ)-5D pain and
symptom, and the ASAS scores [17]. Findings were similar
within the more rigorous context of a randomized, con-
trolled clinical trial (ATLAS) in which there was significant
correlation between the Short Form (SF)-36/Ankylosing
Spondylitis Quality of Life (ASQoL), BASDAI/BASFI,/
Health Utility Index (HUI)-3 scores and WPAI-Specific
Health Problem (SHP) scores, and between the patient’s
and the physician’s global assessment of disease activity and
WPAI-SHP scores [29]. The correlation between the level
of disease activity and work productivity suggests that treat-
ments able to control disease activity would also reduce
disability and loss of productivity [30–34].
Conclusions
As SpA impacts productivity mainly in the prime of pa-
tients' working lives, it is important to increase public
awareness, so that patients will be in a position to seek
timely, appropriate care, which will undoubtedly optimize
their diagnostic and therapeutic outcome.
Additional file
Additional file 1: Anonymous questionnaire (multiple choice questions).
(PDF 56 kb)
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